Telos Rx Reviews: Named Pharmacies, No Monthly Price

The one-sentence version

Telos Rx does the thing nobody else here does — it names both dispensing pharmacies, with street addresses, phone numbers and their state licensure gaps — then fails the thing almost everybody else manages: it publishes no single-month price for anything. The advertised "as low as $116 per month" is the longest plan, the shortest plan named in its own policy is three months, and its footer link labelled "Pricing" returns a 404. It grades B, 9 out of 14, computed from published terms alone and blind to who pays us.

What it is, and who it's for

Telos Rx is a compounded telehealth platform — "a technology and administrative services platform," in its own words, with "medical services… provided by an independent, US-licensed telehealth medical group." It names that group too: Arora Health & Aesthetics, LLC, 300 Lenora Street, Seattle WA. The platform company is Superior Health Solutions LLC.

The catalogue today is seven products: NAD+ nasal spray, sermorelin, PT-141, and a GLP-1 line of tirzepatide, semaglutide, oral tirzepatide and microdosed tirzepatide. A five-minute intake is reviewed by a US-licensed clinician "typically within four hours," and the subscription includes "unlimited messaging with your care team, dose adjustments, and quarterly labs."

The buyer this suits trades price visibility for supply-chain visibility — the opposite trade to most of our provider rankings.

What it actually costs — which is the problem

All figures verified on telosrx.com on 26 July 2026.

NAD+ nasal spray: "As low as $249 $116 per month." Sermorelin: "As low as $299 $125 per month." Under the "Pricing" heading on each product page: "Your price depends on plan length. Cancel anytime, no penalties."

That is the entire pricing disclosure: no table, no ladder. The struck-through $249 and $299 are list prices, and $116 and $125 are floors reachable only on the longest term. What a single month costs is published nowhere — and the footer link labelled "Pricing" resolves to a 404.

The shortest plan may not even be a month. The Shipping & Returns policy (last updated 25 May 2026) refers to "our 3-, 6-, and 12-month plans" — those three, and no other. If a one-month plan exists, it is named on no page we could find, which would make three months the minimum commitment rather than an upgrade.

"No penalties" is contradicted by the policy page. The product page says "Cancel anytime, no penalties." The Shipping & Returns page says: "If you cancel early, the months you've already received are re-priced at the rate of the shortest plan that covers the time you were enrolled, and the difference is charged as a one-time adjustment at cancellation" — its own worked example being a 12-month plan left at month three, re-rated to the 3-month price.

That is a clawback. It is not hidden — Telos publishes it plainly, and never charges for months after cancellation — but two of its own pages disagree about whether leaving costs you anything, and the one a buyer reads first says it does not. See what longevity care costs.

What the subscription does include, and it is generous: free 2-day priority shipping "baked into your plan price," 24/7 unlimited clinician messaging, dose adjustments, quarterly labs at no extra cost, FSA/HSA eligibility, and a "100% refund of any charges" if the clinician determines you do not qualify. Dispensed compounded medication cannot be returned — a federal constraint, not a Telos choice — but quality failures are replaced free within 48 hours.

Clinical oversight and the pharmacy

This is where Telos earns its place. Both dispensing pharmacies are published by name and address:

• •VialsRX, 6220 Westpark Dr, Houston, TX 77057, (713) 497-5590
• •F&F Pharmacies Inc dba Jungle Jim's Pharmacy, 5484 Dixie Highway, Fairfield, OH 45014, (877) 858-3784

And it publishes the second one's limitations rather than burying them: Jungle Jim's "maintain[s] a license in 40 US states," and "cannot dispense sterile compounds and do not have a license in… California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia, and Delaware." A provider volunteering where its own pharmacy cannot serve you is not something we have seen elsewhere here.

The gap is that neither is described as a 503A or a 503B facility — the string "503" appears nowhere on the site. Under our rubric naming without classifying scores one point of two, though the practical position is arguably better than rows scoring two, because a named pharmacy is one you can look up yourself. Telos states the underlying fact plainly: "Compounded medications are compounded, not FDA-approved." FDA agrees — it "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The evidence behind what it sells

The NAD+ page promises "sharper mental focus & clarity," "anti-aging & longevity support," and — most specifically — "Most patients notice changes in energy and mental clarity within the first 2–3 weeks." Its science panel adds that "cellular NAD+ levels drop ~50% between age 40 and 60" and that replenishing it supports "energy, repair, and cognition."

The decline is defensible; the downstream claims are not. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness "inconclusive"². A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time³, and the strongest randomised trial in the field moved six-minute walk distance about 17.6 metres in peripheral artery disease⁴. No completed human trial shows a 2–3 week onset of energy or cognitive benefit.

The sermorelin page promises "recovery, lean muscle, fat metabolism, and deep sleep" from a "nightly subcutaneous protocol" — the precise protocol the relevant trial tested. GHRH 1-29 nightly for six weeks in eleven healthy men aged 64–76 raised nocturnal growth hormone significantly, while producing no change in IGF-1 and no change in DEXA-measured muscle or fat⁵. See NAD+ for longevity, peptides for longevity and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if you need to know what you will be charged: a "from" price you cannot resolve to a plan is the single reason this row grades B rather than A. Skip it if you might not last the term, because the early-exit re-rating will find you. And ask which pharmacy will fill your order if you live in one of the ten states where Jungle Jim's is unlicensed.

If you proceed, get three numbers in writing: the one-month price if one exists, each published plan length's price, and the re-rating you would owe leaving at month three.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Telos Rx takes four for a real longevity line, two for a clinician review inside the price, two for 24/7 messaging and included quarterly labs, and one of two on pharmacy for naming its facilities without classifying them. It takes zero on price transparency, because no plan-level figure is published anywhere. Nine of fourteen. A B.

There is a version of this company that grades an A tomorrow without changing a price: publish the plan table, fix the Pricing link, and make the product page say what the returns page already says about early cancellation. It is frustrating to write a B for the most pharmacy-transparent operator we grade — but a reader cannot spend transparency, and still cannot find out what a month costs. Two neighbours are our yourEra review and Sprout Health review.